KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Receivables: 2014-2025

Historic Change in Receivables for Rigel Pharmaceuticals (RIGL) over the last 9 years, with Sep 2025 value amounting to $6.0 million.

  • Rigel Pharmaceuticals' Change in Receivables rose 260.14% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 118.38%. This contributed to the annual value of $11.1 million for FY2024, which is 213.25% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Change in Receivables is $6.0 million, which was up 466.95% from -$1.6 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Change in Receivables peaked at $126.2 million during Q1 2021, and registered a low of -$124.8 million during Q2 2021.
  • Moreover, its 3-year median value for Change in Receivables was $1.4 million (2024), whereas its average is $509,545.
  • Data for Rigel Pharmaceuticals' Change in Receivables shows a peak YoY increase of 28,087.14% (in 2021) and a maximum YoY decrease of 6,138.85% (in 2021) over the last 5 years.
  • Rigel Pharmaceuticals' Change in Receivables (Quarterly) stood at $481,000 in 2021, then skyrocketed by 5,054.89% to $24.8 million in 2022, then crashed by 71.75% to $7.0 million in 2023, then soared by 57.62% to $11.0 million in 2024, then soared by 260.14% to $6.0 million in 2025.
  • Its Change in Receivables stands at $6.0 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$68,000 for Q1 2025.